CCPA (2‐chloro‐N6‐cyclopentyladenosine, a specific agonist of A1R) treatment (0.05 mg kg−1, i.p.)ameliorated cognitive deficits with respect to memory in Bmal1‐iKO mice (Figure 4I,J; Figure S7A–D, Supporting Information). The gene discussed is BMAL1; the disease is Cognitive impairment.